Pharmaceutical News

RSS

Synthetic biology pioneer wins 2012 Heinz Award

Jay Keasling, a leading authority and pioneer on synthetic biology who has engineered microbial "factories" to manufacture an affordable version of a frontline antimalarial drug and biofuel substitutes for gasoline, diesel and jet fuel, has won a 2012 Heinz Award, which is presented by the Heinz Family Foundation and carries with it a cash prize of $250,000.

13 Sep 2012

Sanofi Aventis receives FDA approval for Aubagio to treat relapsing forms of MS

The U.S. Food and Drug Administration today approved Aubagio (teriflunomide), a once-a-day tablet for the treatment of adults with relapsing forms of multiple sclerosis (MS).

13 Sep 2012

Ibuprofen or acetaminophen may increase risk of hearing loss among women

Headache? Back pain? At the first sign of pain, you might reach for a pain-relieving medicine to sooth your bodily woes. Analgesics are the most frequently used medications in the United States and are commonly used to treat a variety of medical conditions. But although popping a pill may make the pain go away, it may do some damage to your ears.

13 Sep 2012

Pending cases against India's patent laws threaten public health, misinterpret international IP agreements, report says

"Pending cases against India's patent laws threaten public health and misinterpret international intellectual property (IP) agreements," researchers from Queen Mary, University of London argue in a special report published online in the Lancet on Monday, PharmaTimes reports.

13 Sep 2012

Genzyme receives FDA approval for AUBAGIO to treat relapsing forms of MS

Genzyme, a Sanofi company, announced today that the U.S. Food and Drug Administration (FDA) has approved AUBAGIO (teriflunomide) as a new once-daily, oral treatment indicated for patients with relapsing forms of multiple sclerosis (MS).

13 Sep 2012

RPS honors Aston University professor with Pharmaceutical Scientist of the Year Award

Professor Yvonne Perrie, Chair in Drug Delivery at Aston University, Birmingham UK has won the prestigious Royal Pharmaceutical Society's Pharmaceutical Scientist of the Year Award for her contribution to developing a new tuberculosis vaccine.

13 Sep 2012

Zhejiang Hisun Pharmaceuticals, Pfizer launch new joint venture

Pfizer Inc., the world's largest research-based pharmaceutical company, and Zhejiang Hisun Pharmaceuticals, a leading Chinese pharmaceutical company, today announced the launch of Hisun-Pfizer Pharmaceuticals Co., Ltd., a joint venture formed between the two companies to develop, manufacture and commercialize off-patent pharmaceutical products in China and global markets.

13 Sep 2012

Aethic, King's College London to develop first sunscreen based on mycosporine-like amino acids

King's College London has entered into an agreement with skincare company Aethic to develop the first sunscreen based on MAA's (mycosporine-like amino acids), produced by coral.

12 Sep 2012

TPP trade agreement could threaten access to medicines

"Right now, in Leesburg, Va., the office of the U.S. Trade Representative is negotiating a so-called 'trade agreement' -- the 'Trans-Pacific Partnership Agreement' -- that could put the lives of millions of innocent civilians at risk" by potentially limiting access to life-saving medications, including antiretroviral drugs, Robert Naiman, policy director at Just Foreign Policy, writes in the Huffington Post Blog.

12 Sep 2012

MHRA approves Sucampo’s AMITIZA to treat chronic idiopathic constipation in the U.K.

Sucampo Pharmaceuticals, Inc. today announced that it has received approval from the Medicines and Healthcare products Regulatory Agency for AMITIZA (lubiprostone) 24 mcg twice daily for the treatment of chronic idiopathic constipation (CIC) and associated symptoms in adults, when response to diet and other non-pharmacological measures (e.g., educational measures, physical activity) are inappropriate.

12 Sep 2012

Diet could avert toxic effects of quinine in patients with malaria

Scientists at The University of Nottingham say adverse side-effects caused by the anti-parasitic drug quinine in the treatment of malaria could be controlled by what we eat.

12 Sep 2012

Ethypharm, Ampio enter definitive agreement to manufacture Zertane

Ampio Pharmaceuticals, Inc. (AMPE), a clinical stage biopharmaceutical company, with repurposed drugs and new molecular entities (NMEs) that treat inflammatory diseases, including osteoarthritis, diabetic macular edema (DME) and sexual dysfunction announced today that it has entered into a definitive agreement with Ethypharm Ltd for the manufacturing of Zertane, Ampio's drug for the treatment of premature ejaculation.

12 Sep 2012

Comic created to help busy medical staff on the benefits of tranexamic acid

Researchers at the London School of Hygiene & Tropical Medicine have created a comic influenced by the Japanese manga style to help busy medical staff who treat patients suffering from bleeding.

12 Sep 2012

Edison receives EMA COMP orphan designation for EPI-743 to treat Leigh syndrome

Edison Pharmaceuticals announced today that the Committee for Orphan Medicinal Products (COMP), European Medicines Agency, has granted orphan designation to EPI-743 for the treatment of Leigh syndrome.

12 Sep 2012

Inhaled analgesia appears to be effective in reducing pain intensity in first stage of labour

Inhaled pain relief appears to be effective in reducing pain intensity and in giving pain relief in the first stage of labour, say Cochrane researchers.

12 Sep 2012

Omega-3 polyunsaturated fatty acids may not prevent major cardiovascular adverse outcomes

In a study that included nearly 70,000 patients, supplementation with omega-3 polyunsaturated fatty acids was not associated with a lower risk of all-cause death, cardiac death, sudden death, heart attack, or stroke, according to an analysis of previous studies published in the September 12 issue of JAMA.

12 Sep 2012

Berkeley lab researchers link possible new oncogene with resistance to cancer drugs

A gene that may possibly belong to an entire new family of oncogenes has been linked by researchers with the U.S. Department of Energy (DOE)'s Lawrence Berkeley National Laboratory (Berkeley Lab) to the resistance of breast cancer to a well-regarded and widely used cancer therapy.

12 Sep 2012

Pharmaceutical News

Synthetic biology pioneer wins 2012 Heinz Award

Sanofi Aventis receives FDA approval for Aubagio to treat relapsing forms of MS

Ibuprofen or acetaminophen may increase risk of hearing loss among women

Pending cases against India's patent laws threaten public health, misinterpret international IP agreements, report says

Genzyme receives FDA approval for AUBAGIO to treat relapsing forms of MS

RPS honors Aston University professor with Pharmaceutical Scientist of the Year Award

Zhejiang Hisun Pharmaceuticals, Pfizer launch new joint venture

Aethic, King's College London to develop first sunscreen based on mycosporine-like amino acids

TPP trade agreement could threaten access to medicines

MHRA approves Sucampo’s AMITIZA to treat chronic idiopathic constipation in the U.K.

Diet could avert toxic effects of quinine in patients with malaria

Ethypharm, Ampio enter definitive agreement to manufacture Zertane

Comic created to help busy medical staff on the benefits of tranexamic acid

Edison receives EMA COMP orphan designation for EPI-743 to treat Leigh syndrome

Inhaled analgesia appears to be effective in reducing pain intensity in first stage of labour

Omega-3 polyunsaturated fatty acids may not prevent major cardiovascular adverse outcomes

Berkeley lab researchers link possible new oncogene with resistance to cancer drugs

Pfizer, Visterra collaborate to discover novel antibodies

Arsanis to develop monoclonal antibody therapeutics against nosocomial infections

Dengue vaccine breakthrough

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News